PYC Stock Overview
Provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Physiomics Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0075 |
| 52 Week High | UK£0.021 |
| 52 Week Low | UK£0.006 |
| Beta | 1.67 |
| 1 Month Change | 11.11% |
| 3 Month Change | 11.11% |
| 1 Year Change | -53.13% |
| 3 Year Change | -88.81% |
| 5 Year Change | -76.56% |
| Change since IPO | -99.68% |
Recent News & Updates
Recent updates
It's Unlikely That Shareholders Will Increase Physiomics Plc's (LON:PYC) Compensation By Much This Year
Nov 15
Here's Why We Think Physiomics Plc's (LON:PYC) CEO Compensation Looks Fair
Nov 17Here's Why Shareholders Will Not Be Complaining About Physiomics Plc's (LON:PYC) CEO Pay Packet
Nov 16What Can We Conclude About Physiomics' (LON:PYC) CEO Pay?
Feb 08
Shareholder Returns
| PYC | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -6.3% | -5.9% | -2.6% |
| 1Y | -53.1% | -26.2% | 2.4% |
Return vs Industry: PYC underperformed the UK Life Sciences industry which returned -26.2% over the past year.
Return vs Market: PYC underperformed the UK Market which returned 2.4% over the past year.
Price Volatility
| PYC volatility | |
|---|---|
| PYC Average Weekly Movement | 7.9% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: PYC's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: PYC's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 11 | Peter Sargent | www.physiomics.co.uk |
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine.
Physiomics Plc Fundamentals Summary
| PYC fundamental statistics | |
|---|---|
| Market cap | UK£1.52m |
| Earnings (TTM) | -UK£609.35k |
| Revenue (TTM) | UK£570.56k |
2.7x
P/S Ratio-2.5x
P/E RatioIs PYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYC income statement (TTM) | |
|---|---|
| Revenue | UK£570.56k |
| Cost of Revenue | UK£1.22m |
| Gross Profit | -UK£650.12k |
| Other Expenses | -UK£40.77k |
| Earnings | -UK£609.35k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.003 |
| Gross Margin | -113.94% |
| Net Profit Margin | -106.80% |
| Debt/Equity Ratio | 0% |
How did PYC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Physiomics Plc is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi-Ling Liu | Hybridan LLP |
| Alexander Pye | WH Ireland Limited |